Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
8.39
Jul 10 • 04:00PM ET Dollar change-0.05 Percentage change(-0.65%)
Index
-
Market Cap
23.60M
Enterprise Value
20.98M
Income
-25.87M
Sales
20.92M
Book/sh
2.26
Cash/sh
4.06
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
81
IPO
Sep 12, 2014
P/E
-
Forward P/E
-
PEG
-
P/S
1.13
P/B
3.70
P/C
2.06
P/FCF
-
EV/EBITDA
-
EV/Sales
1.00
Quick Ratio
1.82
Current Ratio
2.40
Debt/Eq
1.40
LT Debt/Eq
1.33
Option/Short
No / Yes
EPS (ttm)
-19.68
EPS next Y
-1.75
EPS next Q
-1.39
EPS this Y
66.54%
EPS next Y
60.43%
EPS next 5Y
57.23%
EPS past 3/5Y
13.32% 24.32%
Sales past 3/5Y
58.72% 38.06%
EPS Y/Y TTM
46.19%
Sales Y/Y TTM
-17.67%
EPS Q/Q
-21.11%
Sales Q/Q
-22.07%
Insider Own
46.81%
Insider Trans
0.00%
Inst Own
0.50%
Inst Trans
-2.86%
ROA
-83.16%
ROE
-209.10%
ROIC
-176.25%
Gross Margin
24.59%
Oper. Margin
-83.53%
Profit Margin
-123.66%
SMA20
12.41%
SMA50
16.70%
SMA200
14.53%
Trades
Shs Outstand
2.78M
Shs Float
1.50M
52W High
10.56 -20.60%
52W Low
4.14 102.54%
Volatility
14.06% 7.62%
ATR (14)
0.64
RSI (14)
64.43
Beta
0.37
Rel Volume
0.32
Avg Volume
11.87K
Volume
3,749
Perf Week
4.55%
Perf Month
20.09%
Perf Quarter
26.66%
Perf Half Y
9.99%
Perf YTD
21.18%
Perf Year
-6.90%
Perf 3Y
-87.97%
Perf 5Y
-93.77%
Perf 10Y
-99.95%
Prev Close
8.44
Price
8.39
Change
-0.65%
Date Action Analyst Rating Change Price Target Change
Feb-10-25Initiated Laidlaw Buy $10
Apr-03-17Downgrade Barclays Equal Weight → Underweight $2.50 → $1.50
Dec-16-16Initiated Oppenheimer Outperform
Jul-15-16Initiated Piper Jaffray Overweight $10
May-22-15Upgrade Canaccord Genuity Hold → Buy $11 → $17
May-08-15Reiterated Barclays Equal Weight $20 → $13
Oct-07-14Initiated Barclays Equal Weight $28
Jul-07-26 04:15PM
May-19-26 08:00AM
May-15-26 07:01PM
12:42PM
09:02AM
08:00AM Loading…
08:00AM
May-11-26 09:25AM
May-04-26 08:00AM
Mar-25-26 04:10PM
Mar-18-26 03:02PM
08:17AM
08:00AM
Mar-17-26 09:24AM
Mar-13-26 08:00AM
Mar-11-26 08:00AM
04:15PM Loading…
Mar-10-26 04:15PM
Mar-02-26 08:00AM
Feb-25-26 08:00AM
Feb-20-26 08:00AM
Feb-17-26 08:00AM
Jan-13-26 08:00AM
Dec-19-25 04:05PM
Dec-17-25 08:00AM
Dec-03-25 08:00AM
Nov-17-25 08:00AM
Nov-14-25 04:01PM
08:11AM
08:00AM
Nov-13-25 07:31AM
Nov-10-25 07:00AM
08:45AM Loading…
Sep-09-25 08:45AM
08:30AM
Sep-08-25 08:30AM
Aug-14-25 09:10AM
08:06AM
08:00AM
Aug-13-25 08:00AM
Aug-12-25 06:00PM
Aug-07-25 05:30PM
05:25PM
Aug-06-25 10:50AM
Aug-05-25 06:20PM
Aug-04-25 08:30AM
Jul-07-25 11:00AM
Jun-26-25 04:15PM
09:15AM
Jun-25-25 09:10AM
Jun-24-25 04:05PM
May-20-25 08:00AM
May-19-25 08:30AM
06:00AM
May-16-25 03:08AM
May-15-25 09:15AM
08:00AM
May-08-25 08:30AM
May-07-25 04:30PM
Apr-29-25 08:30AM
Apr-24-25 08:30AM
Apr-16-25 07:13AM
Apr-15-25 08:15AM
Mar-23-25 08:40AM
Mar-13-25 09:15AM
Mar-08-25 02:03AM
Mar-07-25 08:00AM
Mar-06-25 08:00AM
Mar-05-25 08:00AM
Feb-28-25 08:00AM
Feb-19-25 09:10AM
Feb-06-25 08:20AM
Feb-05-25 08:00AM
Feb-04-25 08:00AM
Jan-13-25 08:30AM
07:45AM
Jan-08-25 04:15PM
Jan-07-25 08:05AM
Dec-27-24 05:49PM
Nov-19-24 08:30AM
Nov-13-24 02:08AM
Nov-12-24 08:00AM
Nov-07-24 04:05PM
Nov-05-24 04:38PM
Nov-04-24 08:00AM
Oct-24-24 04:30PM
Sep-24-24 05:00PM
Sep-12-24 08:30AM
Sep-10-24 08:30AM
Sep-05-24 08:30AM
Sep-04-24 04:15PM
Aug-15-24 08:00AM
Aug-08-24 04:15PM
Jul-02-24 04:30PM
Jun-26-24 08:30AM
Jun-11-24 10:50AM
Jun-04-24 04:30PM
May-28-24 03:32AM
May-16-24 08:18AM
May-15-24 09:10AM
08:00AM
May-14-24 12:00PM
May-07-24 04:30PM
Lifeward Ltd. is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm's exoskeletons provide hip and knee motion to enable individuals with spinal cord injury (SCI) to stand upright, walk, turn, and climb and descend stairs. Its products include ReWalk Exo-Suit and ReWalk Personal 6.0. The company was founded by Amit Goffer on June 20, 2001 and is headquartered in Hudson, MA.
PresidentMr. William Mark Grant
Chief Financial OfficerMr. Almog Adar
Vice President of OperationsMs. Miri Pariente
Chief Medical OfficerDr. Keith Dale Rose M.D.
Vice President of SalesMr. Craig Peters DPT
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lynch JeannineVP of Market Access & StrategySep 02 '25Sale0.641,5911,01846,067Sep 04 05:07 PM